Federico Carbone

8PUBLICATIONS
21CO-AUTHORS
Molecular targetsCancer geneticsToxicology (incl. clinical toxicology)Memory and attentionClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 28, 2024
SGLT2 inhibition to target kidney aging.

Elisa Russo, Valentina Zanetti, Lucia Macciò

|May 13, 2024
Inhibition of de novo ceramide synthesis by sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes.

Srividya Velagapudi, Gergely Karsai, Maria Karsai

|Apr 13, 2024
Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.

Federico Carbone, Atbin Djamshidian

|Mar 08, 2024
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.

Alberto Preda, Fabrizio Montecucco, Federico Carbone

|Oct 20, 2022
Cognitive dysfunction 1 year after COVID-19: evidence from eye tracking.

Federico Carbone, Laura Zamarian, Verena Rass

|May 28, 2022
Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone-Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study.

Philipp Ellmerer, Marina Peball, Federico Carbone

Pageof 2

Frequent Collaborators

2 joint publications

Philipp Ellmerer

2 joint publications

Marina Peball

2 joint publications

Beatrice Heim

2 joint publications

Atbin Djamshidian